Last updated: 2026-11-15 19:38:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
MetaVia Inc. (MTVA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.30, with a market capitalization of $8.56M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.97 to $13.42. This page covers its latest market performance, valuation, price trends and company information.
$8.56M | |
$1.37 | |
$1.45 | |
$1.25 | |
$1.30 | |
48.23K | |
114.46K | |
-- | |
$13.42 | |
$0.97 | |
-- | |
-- |
MetaVia Inc. (MTVA) last closed at $1.30 as of 2026-11-14 00:51:00, down 5.26% ($0.07) from the previous close of $1.30.
During the latest regular trading session, MTVA traded between $1.26 and $1.45, with a volume of 48.23K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, MetaVia Inc. (MTVA) moved from $1.09 to $1.30, representing a gain of 19.08% ($0.21).
The stock traded between $1.02 and $1.78 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 409.10 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 2.7%
MTVA is currently trading at $1.30, placing it 2.7% of the way from its 52-week low of $0.97 to its 52-week high of $13.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MetaVia Inc is a clinical-stage biotechnology company focused on developing treatments for liver-related cardiometabolic diseases. Its product pipeline includes DA-1726, an oxyntomodulin analogue that acts as a dual GLP-1 and glucagon receptor agonist, being developed for metabolic and alcohol-associated liver diseases. The company is also developing vanoglipel (DA-1241), a GPR119 agonist, in combination with resmetirom for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 8 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to MetaVia Inc. and MTVA stock.
MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.73) by 5.48 percent. This is a 55.19 percent increase over losses of $(1.54) per share from the same
MetaVia reports positive Phase 1 data showing that once-weekly DA-1726 significantly reduces serum uric acid and liver fat.
DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.
Eligible investors can buy real shares of MetaVia Inc. (MTVA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to MTVA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between MTVA shares and USD.
MTVA Shares to USD
1.00 MTVA shares = 1.298 USD
Calculations are estimates based on the latest available price and are for reference only.
